{"schema_version":"secwatch.filing_event.v1","accession":"0001787306-23-000090","form_type":"8-K/A","ticker":"ARQT","cik":"0001787306","company_name":"Arcutis Biotherapeutics, Inc.","filed_at":"2023-09-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:35.240922+00:00","generated_at":"2026-06-10T22:56:31.236855+00:00","sec_items":["5.02","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Arcutis appoints John Smither as interim CFO with $550K salary, option grant of 125K shares at $8.54","bullets":["Base salary of $550,000 and target annual bonus of 45% of base salary.","Option to purchase 125,000 shares at $8.54 per share, vesting 2.0833% monthly.","Severance provides up to 12 months base salary and bonus, plus COBRA reimbursement, upon qualifying termination during change in control.","Equity awards accelerate 100% upon qualifying termination during change in control period; performance awards vest at greater of target or actual.","Employment effective August 31, 2023; Smither reports to CEO and serves as principal financial and accounting officer."],"urls":{"canonical":"https://secwatch.observer/filing/0001787306-23-000090","json":"https://secwatch.observer/filing/0001787306-23-000090.json","markdown":"https://secwatch.observer/filing/0001787306-23-000090.md","text":"https://secwatch.observer/filing/0001787306-23-000090.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1787306/000178730623000090/0001787306-23-000090-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1787306/000178730623000090/arqt-20230815.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-10T22:56:31.236855+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"1db28a2131","claim":"John Smither was appointed as interim chief financial officer at Arcutis Biotherapeutics, Inc..","evidence_excerpt":"announcing the appointment of John Smither as the Company’s interim chief financial officer, effective as of August 31, 2023","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1787306/000178730623000090/0001787306-23-000090-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"interim chief financial officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}